Lipoxygenase: an emerging target for stroke therapy

Neuroprotection as approach to stroke therapy has recently seen a revival of sorts, fueled in part by the continuing necessity to improve acute stroke care, and in part by the identification of novel drug targets. 12/15- Lipoxygenase (12/15-LOX), one of the key enzymes of the arachidonic acid cascad...

Full description

Saved in:
Bibliographic Details
Published inCNS & neurological disorders drug targets Vol. 12; no. 2; p. 191
Main Author van Leyen, Klaus
Format Journal Article
LanguageEnglish
Published United Arab Emirates 01.03.2013
Subjects
Animals
Arachidonic Acid - metabolism
Enzyme Inhibitors - therapeutic use
Humans
Lipoxygenase - metabolism
Models, Biological
Stroke - drug therapy
Stroke - enzymology
Stroke - pathology
Online AccessGet more information

Cover

More Information
Summary:Neuroprotection as approach to stroke therapy has recently seen a revival of sorts, fueled in part by the continuing necessity to improve acute stroke care, and in part by the identification of novel drug targets. 12/15- Lipoxygenase (12/15-LOX), one of the key enzymes of the arachidonic acid cascade, contributes to both neuronal cell death and vascular injury. Inhibition of 12/15-LOX may thus provide multifactorial protection against ischemic injury. Targeting 12/15-LOX and related eicosanoid pathways is the subject of this brief review.
ISSN:1996-3181
DOI:10.2174/18715273112119990053